Results 71 to 80 of about 498,039 (247)

Molecular Pharmacological Interventions for Endometrial Cancer: A Comprehensive Review

Drug Design, Development and Therapy
Wei Qin,1,* Yazhou Qi,2,* Qianwen Li,2,* Bei Wang,2,* Jingmiao Wang,3 Xueke Ge,3 Yanhong Li,4 Xinyue Zhang,4 Kuan Liu4 1Internal Medicine of Integrated Chinese and Western Medicine, Affiliated Hospital of Hebei University,
Qin W, Qi Y, Li Q, Wang B, Wang J, Ge X, Li Y, Zhang X, Liu K   +8 more
doaj  

MLC parameters from static fields to VMAT plans: an evaluation in a RT-dedicated MC environment (PRIMO)

Radiation Oncology, 2019
Background PRIMO is a graphical environment based on PENELOPE Monte Carlo (MC) simulation of radiotherapy beams able to compute dose distribution in patients, from plans with different techniques. The dosimetric characteristics of an HD-120 MLC (Varian),
Lucia Paganini, Giacomo Reggiori, Antonella Stravato, Valentina Palumbo, Pietro Mancosu, Francesca Lobefalo, Anna Gaudino, Antonella Fogliata, Marta Scorsetti, Stefano Tomatis   +9 more
doaj   +1 more source

Evaluation of plan adaptation strategies for stereotactic radiotherapy of lymph node oligometastases using online magnetic resonance image guidance

Physics and Imaging in Radiation Oncology, 2019
Background and purpose: Recent studies have shown that the use of magnetic resonance (MR) guided online plan adaptation yields beneficial dosimetric values and reduces unplanned violations of the dose constraints for stereotactic body radiation therapy ...
Dennis Winkel, Gijsbert H. Bol, Anita M. Werensteijn-Honingh, Ilse H. Kiekebosch, Bram van Asselen, Martijn P.W. Intven, Wietse S.C. Eppinga, Bas W. Raaymakers, Ina M. Jürgenliemk-Schulz, Petra S. Kroon   +9 more
doaj   +1 more source

Cell surface interactome analysis identifies TSPAN4 as a negative regulator of PD‐L1 in melanoma

Molecular Oncology, EarlyView.
Using cell surface proximity biotinylation, we identified tetraspanin TSPAN4 within the PD‐L1 interactome of melanoma cells. TSPAN4 negatively regulates PD‐L1 expression and lateral mobility by limiting its interaction with CMTM6 and promoting PD‐L1 degradation.
Guus A. Franken, Andrea Abel Gutierrez, Imke van Rossum, Cornelia G. Spruijt, Michiel Vermeulen, Guido van Mierlo, Blanca Scheijen, Annemiek B. van Spriel   +7 more
wiley   +1 more source

PARP inhibition and pharmacological ascorbate demonstrate synergy in castration‐resistant prostate cancer

Molecular Oncology, EarlyView.
Pharmacologic ascorbate (vitamin C) increases ROS, disrupts cellular metabolism, and induces DNA damage in CRPC cells. These effects sensitize tumors to PARP inhibition, producing synergistic growth suppression with olaparib in vitro and significantly delayed tumor progression in vivo. Pyruvate rescue confirms ROS‐dependent activity.
Nicolas Gordon, Peter T. Gallagher, Orly I. Richter, Neermala Poudel Neupane, Amy C. Mandigo, Jennifer J. McCann, Emanuela Dylgjeri, Irina Vasilevskaya, Christopher McNair, Channing J. Paller, Wm. Kevin Kelly, Karen E. Knudsen, Matthew J. Schiewer, Ayesha A. Shafi   +13 more
wiley   +1 more source

Individual lymph nodes: “See it and Zap it”

Clinical and Translational Radiation Oncology, 2019
Background and purpose: With magnetic resonance imaging (MRI)-guided radiotherapy systems such as the 1.5T MR-linac the daily anatomy can be visualized before, during and after radiation delivery.
Dennis Winkel, Anita M. Werensteijn-Honingh, Petra S. Kroon, Wietse S.C. Eppinga, Gijsbert H. Bol, Martijn P.W. Intven, Hans C.J. de Boer, Louk M.W. Snoeren, Jochem Hes, Bas W. Raaymakers, Ina M. Jürgenliemk-Schulz   +10 more
doaj   +1 more source

LDAcoop: Integrating non‐linear population dynamics into the analysis of clonogenic growth in vitro

Molecular Oncology, EarlyView.
Limiting dilution assays (LDAs) quantify clonogenic growth by seeding serial dilutions of cells and scoring wells for colony formation. The fraction of negative wells is plotted against cells seeded and analyzed using the non‐linear modeling of LDAcoop.
Nikko Brix, Daniel Samaga, Katharina Gehr, Benedek Dankó, Mohamed Schumann, Guido Drexler, Ahmed Alnatsha, Georg Beyer, Ujjwal Mahajan, Martin Selmansberger, Julia Mayerle, Claus Belka, Horst Zitzelsberger, Kirsten Lauber   +13 more
wiley   +1 more source

Fetal Brain Tumor Harboring a Unique ROCK1::BRAF Fusion

Pediatric Blood &Cancer, EarlyView.
Marllon Cindra Sant'Ana, Mariana Maschietto, Daniela Paz Leal, Ricardo de Santos de Oliveira, Mayara Ferreira Euzébio, Antonio Carlos dos Santos, Luciano Neder, Carlos Alberto Scrideli, Elvis Terci Valera   +8 more
wiley   +1 more source

Plecstatin inhibits hepatocellular carcinoma tumorigenesis and invasion through cytolinker plectin

Molecular Oncology, EarlyView.
The ruthenium‐based metallodrug plecstatin exerts its anticancer effect in hepatocellular carcinoma (HCC) primarily through selective targeting of plectin. By disrupting plectin‐mediated cytoskeletal organization, plecstatin inhibits anchorage‐dependent growth, cell polarization, and tumor cell dissemination.
Zuzana Outla, Jan Kosla, Magdalena Prechova, Lukas Frick, Patricia Bortel, Yasmin Borutzki, Andrea Bileck, Christopher Gerner, Samuel M. Meier‐Menches, Selma Osmanagic‐Myers, Martin Gregor   +10 more
wiley   +1 more source

Therapeutic strategies for MMAE‐resistant bladder cancer through DPP4 inhibition

Molecular Oncology, EarlyView.
We established monomethyl auristatin E (MMAE)‐resistant bladder cancer (BC) cell lines by exposure to progressively increasing concentrations of MMAE in vitro. RNA sequencing showed DPP4 expression was increased in MMAE‐resistant BC cells. Both si‐DPP4 and the DPP4 inhibitor sitagliptin suppressed the viability of MMAE‐resistant BC cells.
Gang Li, Shuichi Tatarano, Hirofumi Yoshino, Saeki Saito, Mitsuhiko Tominaga, Junya Arima, Ikumi Fukuda, Takashi Sakaguchi, Ryosuke Matsushita, Yasutoshi Yamada, Hideki Enokida   +10 more
wiley   +1 more source